Mergers & acquisitions once again took center stage in the biotech sector with Alexion (ALXN – Analyst Report) announcing its intention to acquire Synageva (GEVA – Snapshot Report). Meanwhile, there were some important updates on the regulatory and pipeline front from companies like Vertex (VRTX – Analyst Report) and Orexigen (OREX – Analyst Report).Recap of the Week’s Most Important Stories1. […]
Please choose a subscription
Breaking News
CNBC’s latest news headlines
Morning Squawk
Daily before the bell news roundup
Evening Brief
Daily recap of the day’s top headlines
Guest Alerts
Guest information & reminders for your calendar
Your Wealth
Weekly advice on managing your money
Options Action
Insight from the Options Action panelJob IndustryAdvertising/MarketingAutomotiveCommunications/PRConstruction/ManufacturingEducationFinance/Banking/InsuranceLegalMedia/EntertainmentMedical/Health CareMining/Oil/Gas/UtilitiesGov’t/Non-ProfitReal EstateRetailTechnology/ITTransportation/ShippingTravel/HospitalityOther
View article:
Are leveraged ETFs making biotech stocks sick? – CNBC.com
[…]
It’s been a turbulent few days for the biotech sector with the NASDAQ Biotechnology Index declining 5.46% over the last five trading days. A major part of this decline was recorded on Monday as the sector reacted to negative pipeline updates from companies like Amgen (AMGN – Analyst Report) and Celladon (CLDN – Snapshot Report). Meanwhile, Biogen’s (BIIB – Analyst […]
The biotech segment has been growing well surpassing all expectations until Monday when shares slipped significantly. The NASDAQ Biotechnology Index ^NBI and NYSE ARCA BIOTECH INDEX ^BTK had gained 16.7% and 18.7%, respectively, til Apr 24 but both declined more than 4% on Monday after disappointing news from several biotech companies.Just when news of several mergers & acquisitions, product approvals […]
Original article:
Biotech Stocks With Elliott-wave Forecasting | EconMatters
[…]
Biotech Stocks and the Power of ContextInvestorEducation / Elliott Wave TheoryApr 27, 2015 – 10:13 PM GMTBy: EWIBiotech stocks: A real-life example of Elliott-wave forecasting at several degrees of trendSince joining Elliott Wave International in 1993, the editor of our Trader’s Classroom, Jeffrey Kennedy, has traveled to at least a dozen countries, teaching seminars to some of the best professional […]
Biotech stocks have been surging since their mid-March plunge (back below the 50DMA), but it appears that is at an end as XBI – the SPDR Biotech ETF – is now down almost 7% from Friday’s highs on heavy volume (and back below the 50DMA once again).Which has smashed XBI back below its 50DMA on very heavy volume..This is a […]
Google FinanceShares of Aerie Pharmaceuticals erased more than two-thirds of their value in a few minutes late on Thursday.The stock closed nearly 2% higher at $35.39 per share, giving the company a market value of $850 million. Then shortly after the end of trading, the company announced that Rhopressa, an experimental eye drop, failed a late-stage test.In after-hours trading, shares crashed by more […]
Google FinanceShares of Aerie Pharmaceuticals erased more than two-thirds of their value in a few minutes late on Thursday.The stock closed nearly 2% higher at $35.39 per share, giving the company a market value of $850 million. Then shortly after the end of trading, the company announced that Rhopressa, an experimental eye drop, failed a late-stage test.In after-hours trading, shares crashed by more […]
Are Biotech Stocks in a Bubble?By: David Chapman | Thu, Apr 23, 2015SharePrintEmailCharts created using Omega TradeStation 2000i. Chart data supplied by Dial DataAre Biotech stocks in a bubble? This is a question that is being asked. According to an article by Bloomberg (Biotech Index in Nosebleed Territory – Up 500% In 4-years, Trades At 10X Revenues – Bloomberg Business, […]
